- Home
- ADAP vs ADVB Comparison
ADAP vs ADVB Comparison
Compare ADAP & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- ADVB
- Stock Information
- Founded
- ADAP 2008
- ADVB 2014
- Country
- ADAP United Kingdom
- ADVB United States
- Employees
- ADAP N/A
- ADVB N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- ADAP Health Care
- ADVB Health Care
- Exchange
- ADAP Nasdaq
- ADVB Nasdaq
- Market Cap
- ADAP 71.6M
- ADVB 79.0M
- IPO Year
- ADAP 2015
- ADVB 2025
- Fundamental
- Price
- ADAP $0.24
- ADVB $1.81
- Analyst Decision
- ADAP Strong Buy
- ADVB
- Analyst Count
- ADAP 5
- ADVB 0
- Target Price
- ADAP $1.83
- ADVB N/A
- AVG Volume (30 Days)
- ADAP 2.6M
- ADVB 77.1K
- Earning Date
- ADAP 05-14-2025
- ADVB 01-01-0001
- Dividend Yield
- ADAP N/A
- ADVB N/A
- EPS Growth
- ADAP N/A
- ADVB N/A
- EPS
- ADAP N/A
- ADVB N/A
- Revenue
- ADAP $178,032,000.00
- ADVB N/A
- Revenue This Year
- ADAP N/A
- ADVB N/A
- Revenue Next Year
- ADAP $65.49
- ADVB N/A
- P/E Ratio
- ADAP N/A
- ADVB N/A
- Revenue Growth
- ADAP 195.34
- ADVB N/A
- 52 Week Low
- ADAP $0.20
- ADVB $1.47
- 52 Week High
- ADAP $1.48
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- ADAP 37.78
- ADVB N/A
- Support Level
- ADAP $0.23
- ADVB N/A
- Resistance Level
- ADAP $0.26
- ADVB N/A
- Average True Range (ATR)
- ADAP 0.04
- ADVB 0.00
- MACD
- ADAP 0.01
- ADVB 0.00
- Stochastic Oscillator
- ADAP 31.85
- ADVB 0.00
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.